Portal Enables Novel Insights in Drug Discovery

Portal & AbbVie: Unlocking Intracellular Insights for Drug Discovery

See how Portal and Promega are enabling AbbVie to test impermeable small molecules, protein degraders, and gene editing constructs directly inside living cells — bypassing traditional permeability limitations to accelerate early drug discovery decisions.

What You'll Learn:

How mechanoporation enables structure-activity relationship (SAR) studies for impermeable small molecules and protein degraders that can't cross the cell membrane on their own
How Portal delivers Promega's impermeable NanoBRET tracers to enable intracellular target engagement assays for mechanistic studies
How Portal facilitates CRISPR knock-in experiments to support functional genomics workflows
How Portal's technology platform provides a single solution spanning compound delivery, live-cell assays, and gene editing

Armon Sharei, Ph.D.
Founder and CEO
Armon Sharei, Ph.D.
Founder and CEO